p53 mutations and prognosis in bladder tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Loss of heterozygosity (LOH) on chromosome 17p and p53 gene mutations are implicated in various cancers.
• Understanding their role in bladder tumorigenesis is crucial for prognosis.

Purpose of the Study:

• To investigate the incidence of 17p LOH and p53 mutations in bladder tumors.
• To correlate these genetic alterations with histological findings, smoking status, and patient prognosis.

Main Methods:

• Analysis of 43 bladder tumor patients.
• Assessment of LOH at 17p13 and p53 gene mutations.
• Correlation with tumor grade, stage, smoking history, and survival data.

Main Results:

• 50% of informative cases showed 17p LOH, predominantly in tumors beyond stage pT2.
• 46.5% of patients had p53 mutations, often in high-grade and invasive tumors (beyond grade 2 and stage pT2).
• G:C to T:A substitutions in p53 mutations were observed in smokers, suggesting a link between smoking and specific mutation types.

Conclusions:

• Genetic alterations in chromosome 17p and p53 mutations are more frequent in high-grade and invasive bladder tumors.
• Cigarette smoking may be a factor in the development of p53 gene mutations in bladder cancer.
• p53 gene mutations are potential prognostic markers for bladder tumors, independent of histopathological findings.